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Abstract
Background: Lethal multiple pterygium syndrome (LMPS, OMIM 253290), is a fatal disorder associated with
anomalies of the skin, muscles and skeleton. It is characterised by prenatal growth failure with pterygium present in
multiple areas and akinesia, leading to muscle weakness and severe arthrogryposis. Foetal hydrops with cystic
hygroma develops in affected foetuses with LMPS. This study aimed to uncover the aetiology of LMPS in a family
with two affected foetuses.
Methods and results: Whole exome sequencing studies have identified novel compound heterozygous mutations
in RYR1 in two affected foetuses with pterygium, severe arthrogryposis and foetal hydrops with cystic hygroma,
characteristic features compatible with LMPS. The result was confirmed by Sanger sequencing and restriction
fragment length polymorphism analysis.
Conclusions: RYR1 encodes the skeletal muscle isoform ryanodine receptor 1, an intracellular calcium channel with
a central role in muscle contraction. Mutations in RYR1 have been associated with congenital myopathies, which
form a continuous spectrum of pathological features including a severe variant with onset in utero with fetal
akinesia and arthrogryposis. Here, the results indicate that LMPS can be considered as the extreme end of the RYR1-
related neonatal myopathy spectrum. This further supports the concept that LMPS is a severe disorder associated
with defects in the process known as excitation-contraction coupling.
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Background
Autosomal recessive multiple pterygium syndrome
(MPS), is a rare but severe disorder associated with
anomalies of the skin, muscles and skeleton [1]. There
are two forms of MPS, multiple pterygium syndrome
Escobar type, (EVMPS, OMIM 26500) the milder form,
also referred to as Escobar syndrome, and lethal multiple
pterygium syndrome (LMPS, OMIM 253290), the severe
form which is fatal before birth or very soon after birth.
LMPS has many of the same signs and symptoms as the
Escobar type [1]. It is characterised by prenatal growth
failure with webbing of the skin (pterygium) present in
multiple areas and a lack of muscle movement (akinesia)
leading to muscle weakness and severe arthrogryposis.
In addition, affected foetuses with LMPS develop foetal
hydrops with cystic hygroma [1–3]. LMPS is associated
with abnormalities such as hypoplasia of the heart, lung,
or brain; intestinal malrotation; kidney abnormalities;
cleft palate; and microcephaly. Affected individuals may
also develop other anomalies including congenital dia-
phragmatic hernia, small chest, cryptorchidism, hypo-
plastic dermal ridges and creases, and more occasionally
midforehead haemangioma [1, 4]. Facial anomalies in-
clude hypertelorism, epicanthal folds, flat nasal root,
microretrognathism and microstomia, down-slanting
palpebral fissures, low-set malformed ears, and cleft pal-
ate. LMPS is typically fatal in the second or third trimes-
ter of pregnancy. It shows phenotypic overlap with the
foetal akinesia deformation sequence syndrome (FADS,
OMIM 208150) [5, 6].
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Mutations in genes encoding components of the
neuromuscular junction (NMJ) have been described in
FADS and/or LMPS. This includes mutations in the
genes CHRNA1 (OMIM 100690) [7], CHRND (OMIM
100720) [7] and CHRNG (OMIM 100730) [8], encoding
the alpha, delta and gamma subunits of the acetylcholine
receptor (AChR), respectively. In addition, mutations in
RAPSN (OMIM 601592) [3], encoding a postsynaptic
protein that connects and stabilizes AChR at the NMJ,
DOK7 (OMIM 610285) [9] and recently identified MuSK
[10], encoding muscle skeletal receptor tyrosine kinase,
have been associated with LMPS and/or FADS.
Here we report the association of the skeletal
muscle isoform ryanodine receptor 1, an intracellular
calcium channel encoded by RYR1, with characteristic
LMPS in two foetuses. The foetuses resulted from
two pregnancies of non-consanguineous healthy par-
ents of Iranian Caucasian descent. The first pregnancy
was terminated at 18 and the second at 13 weeks of
gestational age. The results support the concept that
LMPS is a severe disorder associated with defects in
the process known as excitation-contraction coupling.
Case 1
Case 1 is a female foetus resulted from the first preg-
nancy of non-consanguineous, healthy, 28-year-old
parents of Iranian Caucasian descent. The mother
reported reduced foetal movement. Prenatal ultra-
sound examination at 18 weeks of gestation revealed
cystic hygroma, pleural effusion and ascites compat-
ible with hydrops fetalis. The pregnancy was termi-
nated and the foetus and placenta were undertaken
for post-mortem and cytogenetic studies. The foetus
showed cystic hygroma, contractures in the elbows, hip
and knees with pterygium in the elbows (Fig. 1a–c). Two
cultures were set up from muscle tissue, which revealed
normal 46,XX pattern. DNA was extracted from muscle
tissue to perform array Comparative Genomic Hybridisa-
tion (aCGH) for the detection of chromosomal aberra-
tions. The results indicated no genomic imbalance
exceeding 0.5 MB in size.
Case 2
Case 2 is the product of the second pregnancy of the
couple. Ultra-sound examination at 12 weeks gestational
weeks reported cystic hygroma and subcutaneous
oedema in the skull thorax and abdomen. Pleural ascites
and ascites were not seen. Therapeutic abortion was per-
formed at 13 weeks of gestation. Grossly the second
foetus showed cystic hygroma, contractures in the el-
bows, hip and knees with pterygium in the elbows
(Fig. 1d–f ). DNA was extracted from foetal tissue for
molecular studies.
Fig. 1 Frontal and lateral view of case 1 and 2. Contracture in elbows and knees are evident in both foetuses (a, b, d, e), clubfeet is evident in
case 1 (a). Note cystic hydromel (c). Pterygium is evident in the elbows (f)
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Autopsy of case 1
The foetus weighed 135 g (8th centile), was 17,5 (<5th
centile) cm crown-heel length and 11.5 cm (<5th centile)
crown-rump length. The head, chest and abdomen cir-
cumferences were 15, 13.5, and 12 cm, respectively. In
head, the fontanels were patent. The eyes were widely
set. The ears, nose and mouth were normal. The palate
was intact. The chin was small and retracted. The lips
and nail beds were normal. The neck showed large cystic
hygroma. The thorax and abdomen showed subcutane-
ous oedema. The extremities were proportioned, each
furnished by five fingers or toes. They showed joint con-
tractures predominantly in shoulders, elbows, hips and
knees. Webbing of elbows and knees were also seen. Bi-
lateral club-feet was evident. The external genitalia was
that of a female foetus. Anus is patent.
The diaphragm, oesophagus, thymus, cardiovascular
and respiratory systems, gastrointestinal and genitouri-
nary tracts, liver, spleen, pancreas, internal genitalia, and
central nervous system were normal. The serosal cavities
contained serosal yellowish effusion. Microscopic exami-
nations of the lung, thymus, liver, kidneys, spleen, bowel
wall and pancreas were unremarkable. Unfortunately
muscle tissue was not available for microscopy examin-
ation at the autopsy.
Autopsy of case 2
Autopsy was not performed in case 2 due to the small
size of the organs.
Methods
DNA isolation
Extraction of genomic DNA was performed from whole
blood from parents and limb muscle tissue from foe-
tuses, using DNeasy Blood & Tissue kit (Qiagen, Hilden
Germany), according to the manufacturer’s instructions.
In addition, genomic DNA was extracted from 120
Iranian blood donors, who served as controls.
Genetic analysis
Exome sequence analysis
Whole Exome Sequencing (WES) was performed on
DNA from foetuses and their unaffected nonconsangui-
neous parents. Target enrichment was performed with
3 μg genomic DNA using the Sure SelectXT Human All
Exon kit version 4 (Agilent Technologies, Santa Clara,
CA, USA) was used to generate barcoded whole-exome
sequencing libraries. Libraries were sequenced on the
HiSeq2000 platform (Illumina, San Diego, CA, USA) as
paired-end 100-bp reads with 30x coverage. Quality
assessment of the sequence reads was performed by
generating QC statistics with FastQC (http://www.bioin-
formatics.bbsrc.ac.uk/projects/fastqc). Read alignment to
the reference human genome (hg19, UCSC assembly,
February 2009) was done using BWA [11] with default
parameters. After removal of PCR duplicates (Picard
tools, http://picard.sourceforge.net) and file conversion
(samtools [12]) quality score recalibration, indel realign-
ment and variant calling were performed with the GATK
package [13].
Variant annotation and selection
Variants were annotated with ANNOVAR [14] using a
wide range of databases such as dbSNP build 135,
dbNSFP, KEGG, the Gene Ontology project and tracks
from the UCSC. A filtering strategy, directed to disease
gene candidates, was performed by QIAGEN’s Ingenuity®
Variant Analysis™ software (www.qiagen.com/ingenuity)
from QIAGEN Redwood City. We focused on exonic
variants where the mutation produced a missense
change, stop gain or stop loss. We required at least two
mutations in the same gene for further analysis. Only
those changes that were predicted to be damaging or
with unknown impact were kept. We excluded SNPs
that were shared with our control dataset (>1 % in
dpSNP, the Exome Variant Server (NHLBI), the 1000
Genome Project Database and the human Background
Variant DataBase (http://neotek.scilifelab.se/hbvdb/)) as
well as those labelled as compound heterozygous.
Polymerase chain reaction (PCR) and Sanger sequencing
The variants found by whole-exome sequencing in the
candidate genes were examined in the individuals by
PCR and Sanger sequencing using an ABI 3730XL
(GATC Biotech, Constance, Germany and Eurofins
MWG Operon, Ebersberg, Germany) if they had a) a
variant frequency <1 % in the healthy population or b) a
minor allele frequency (MAF) normal MAF in the
European population in EVS. Polymerase chain reac-
tion (PCR) was performed on DNA samples from foe-
tuses and their unaffected parents and 120 control
individuals. PCR primers are available on request.
Restriction fragment length polymorphism (RFLP)
DNA samples isolated from 120 Iranian blood donors
served as controls. The appearance of the missense and
nonsense RYR1 mutations was evaluated by RFLP ana-
lysis in the foetuses and their parents and in the 240
control chromosomes. Loss of a BsrI restriction enzyme
site was used to assess the RYR1 mutation c.4567A > C
(ACT > CCT), (p.Thr1523Pro) in the foetuses and their
parents and in 120 control individuals by digesting a
RYR1 exon 31 PCR product with Bsr I. Similarly, loss of
a BccI restriction enzyme site was used to evaluate the
nonsense RYR1 mutation c.9851G > A (TGG > TAG),
(p.Trp3284Ter) in the foetuses and their parents and in
120 control individuals by digesting a RYR1 exon 66
PCR product with BccI.
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Results
Genetic findings
Data from WES on DNA from foetuses and their par-
ents were analysed through the use of the Ingenuity
Variant Analysis (IVA) software (Qiagen, Hilden
Germany). The filtering strategy narrowed the starting
255331 variants (17848 genes) to 11 genes. This ap-
proach allowed the identification of two novel heterozy-
gous mutation in RYR1 (Accession: AB209425, GI:
62088429); a novel heterozygous A to C change affecting
the highly conserved nucleotide of exon 31 (c.4567A >
C) predicted to result in a substitution of the polar un-
charged threonine at position 1523 to the nonpolar pro-
line (p.Thr1523Pro), located within the N-terminal, and
a novel heterozygous nonsense mutation (c.9851G > A)
in exon 66, which changes aromatic nonpolar trypto-
phan at position 3284 to a stop codon (p.Trp3284Ter),
located at the C-terminal. The unaffected father was het-
erozygous for the c.4567A > C mutation and the
c.9851G > A mutation was inherited from the unaffected
mother (c.9851G > A). None of the mutations was re-
ported in public databases as a polymorphism. Putative
deleterious heterozygous variants in RYR1 exons 31 and
66, were confirmed in the foetuses and their parents by
PCR, RFLP analysis and Sanger sequencing. RFLP ana-
lysis excluded the RYR1 sequence variants in 240 control
chromosomes.
Discussion
Lethal multiple pterygium syndrome is a severe disorder
with a heterogeneous range of manifestations associated
with anomalies of skin, muscle and skeleton. It is charac-
terised by growth deficiency of prenatal onset with mul-
tiple pterygia and flexion contractures as the universal
findings, causing severe arthrogryposis, and foetal akin-
esia. In addition, developmental defects including car-
diac hypoplasia, cleft palate, cryptorchidism, intestinal
malrotation and microcephaly can be present. In severe
cases, subcutaneous oedema may cause foetal hydrops
with cystic hygroma and lung hypoplasia [2, 3, 15].
FADS, also known as Pena-Shokeir syndrome type I,
closely resemble LMPS. Findings that differentiate LMPS
from FADS are fetal hydrops and cystic hygroma. Pter-
gium is a constant feature of LMPS while it can also be
found in some FADS cases.
So far, mutations in the genes encoding proteins in-
volved with neuromuscular transmission are the identi-
fied genetic causes of MPS, LMPS and FADS [3, 7, 8].
Moreover, two recent studies revealed association of
RYR1 in four families with FADS/LMPS [16, 17].
Here, we report novel compound missense and non-
sense mutations in RYR1 in two foetuses with autopsy
findings compatible with characteristic LMPS. The
foetuses resulted from two pregnancies of non-
consanguineous healthy parents, which were terminated
at 18 and 13 weeks of gestational age, respectively.
Ryanodine receptor 1, encoded by RYR1, is the skeletal
muscle isoform expressed in the sarcoplasmic reticulum
and it functions as a calcium release channel. It is in-
volved in the excitation contraction coupling process
and it is composed of two domains: a cytoplasmic do-
main and a transmembrane pore-forming domain. A
group of congenital myopathy and anaesthesia-related
malignant hyperthermia are allelic disorders associated
with genetic defects in RYR1 (OMIM 180901) [18, 19].
Congenital myopathies associated with RYR1 form a
continuous spectrum of pathological features that span
central core disease, congenital fibre type disproportion,
multiminicore disease, and congenital myopathies with
prominent nuclear internalisation and large areas of
myofibrillar disorganisation initially diagnosed as centro-
nuclear myopathy [18]. A severe central core disease
with foetal akinesia has been associated with mutations
in RYR1 [20]. Accordingly, the LMPS can be considered
as the ultimate end of phenotypes associated with RYR1
mutations. Association of LMPS with mutations in genes
encoding subunits of the AChR, RAPS, encoding a post-
synaptic protein that connects and stabilizes AChR at
the NMJ, and RYR1 may indicate that LMPS may be
considered as a disease of ion channel.
Apart from congenital myopathy, heterozygous vari-
ants in RYR1 are known cause of susceptibility to malig-
nant hyperthermia, a potentially lethal disorder of
skeletal muscle calcium homeostasis [19]. However,
there was no history of malignant hyperthermia in either
of the parents of the foetuses, probably due to low pene-
trance of this condition. This can also be explained by
the possible influence of several genes on the susceptibil-
ity to malignant hyperthermia rather than association of
malignant hyperthermia with a major gene defect, as
phenotypic and genotypic data are not always concord-
ant. Interestingly, malignant hyperthermia was described
as a major complication before death in a brother and a
sister with LMPS [21]. It is likely that the LMPS com-
bined with the malignant hyperthermia observed in this
sibling was associated with mutation in RYR1.
Conclusion
In conclusion, our result confirms that LMPS is an allelic
disorder of anaesthesia-related malignant hyperthermia, a
group of congenital myopathies and foetal akinesia syn-
drome, associated with genetic defects in RYR1.
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